Meeting

Workshop: Extending the Spectrum of Precompetitive Oncology Biomedical Research

When:

Tuesday, February 09, 2010 - Wednesday, February 10, 2010 (8:00 AM)

Where:

Keck Center • 500 Fifth St. NW, Washington, DC 20001 Map

Topic(s):

Biomedical and Health Research, Diseases, Health Care Workforce, Health Services, Coverage, and Access, Quality and Patient Safety

Activity:

National Cancer Policy Forum

Board(s):

Board on Health Care Services

Day 1: February 9, 2010 (8:00 am – 5:00 pm)

The National Cancer Policy Forum is holding a public workshop addressing the widening spectrum of precompetitive collaboration in oncology biomedical research and development. Over the last decade, biomedical research and drug development costs have skyrocketed, despite falling productivity evidenced by increasing drug development timelines and decreasing new molecular entity approvals. Increased precompetitive collaboration is a potential driver for innovation and improved productivity. Recent developments in the field of biomedical research and drug development, including the implementation of one-on-one consortia, network models, and larger scale consortia highlight the increasing role that competitive and precompetitive collaboration is assuming within biomedical research and drug development.

Workshop presentations and discussions will provide a general characterization of the precompetitive collaboration environment as well as examples of precompetitive collaboration in science, biomedicine, and oncology. The concluding panel will be devoted to exploring how we can leverage prior experiences to facilitate future precompetitive collaboration opportunities.

The Roundtable on Translating Genomic-Based Research for Health will be hosting a related workshop July 22, 2010 in Washington, D.C.

Confirmed Speakers
· Jill Altshuler, M.B.A., AltshulerGray
· Neal Cohen, M.D., M.P.H., M.S., University of California, San Francisco School of Medicine

· Gregory Curt, M.D., AstraZeneca and CEO Roundtable on Cancer Life Sciences Consortium

· Stephen Friend, M.D., Ph.D., Sage Bionetworks
· Pearl Huang, Ph.D., Merck & Co., Inc.
· Gary Kelloff, M.D., NCI Cancer Imaging Program
· Karim Lakhani, Ph.D., M.S., Harvard Business School
· Mark McClellan, M.D., Ph.D., Brookings Institution’s Engelberg Center for Health Care Reform
· Bernard Munos, M.B.A., Ph.D., Eli Lilly & Co.
· William Spencer, Ph.D., Chairman Emeritus, SEMATECH
· Joseph Vockley, Ph.D., The Cancer Genome Atlas
· David Wholley, M. Phil., The Biomarkers Consortium
· Ray Woosley, M.D., Ph.D., Critical Path Institute

Planning Committee
· John Wagner, M.D., Ph.D., Merck & Co., Inc. (Chair)
· Anna Barker, Ph.D., National Cancer Institute
· Stephen Eck, M.D., Ph.D., Eli Lilly & Co.
· Stephen Friend, M.D., Ph.D., Sage Bionetworks
· Geoff Ginsburg, M.D., Ph.D., Duke University
· Roy Herbst, M.D., Ph.D., MD Anderson
· Sharon Murphy, M.D., IOM Scholar-in-Residence